NASDAQ:IFRX - Get Free Report ) will be issuing its quarterly earnings data before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.
Get InflaRx alerts:
Sign Up
InflaRx (NASDAQ:IFRX - Get Free Report ) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.10). On average, analysts expect InflaRx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
InflaRx Stock Performance Shares of InflaRx stock traded up $0.04 on Wednesday, hitting $1.41. 184,265 shares of the company's stock were exchanged, compared to its average volume of 233,151. The company has a 50-day simple moving average of $1.53 and a 200-day simple moving average of $1.57. The stock has a market capitalization of $83.02 million, a PE ratio of -1.64 and a beta of 1.27. InflaRx has a 1 year low of $1.14 and a 1 year high of $5.20.
Wall Street Analysts Forecast Growth Separately, HC Wainwright reiterated a "buy" rating and set a $8.00 price target on shares of InflaRx in a research note on Friday, March 22nd.
Get Our Latest Analysis on IFRX
InflaRx Company Profile (
Get Free Report )
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
Featured Articles
Before you consider InflaRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InflaRx wasn't on the list.
While InflaRx currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
